Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Pevifoscorvir Sodium in Renal Impairment
NCT07342881Phase 1Completed
- Sponsor
- Aligos Therapeutics
- Start
- Mar 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pevifoscorvir in Chronic Hepatitis B (CHB) (2 arms), sponsored by Aligos Therapeutics. Primary endpoints: Area under the concentration time curve up to 4 days, Maximum plasma concentration up to 4 days and 8 more. Started Mar 2026; status: completed.
02
Drugs
pevifoscorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07342881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342881.